Vaccination of children against coronavirus infection caused by SARS-CoV-2

Abstract

The novel coronavirus infection (COVID-19) is currently a widespread disease in all countries of the world. The adult population is predominantly involved in the epidemic process. In children, the disease proceeds, as a rule, in asymptomatic, mild and moderate forms. However, severe forms of the disease with the development of adverse outcomes are possible. Severe forms of infection are more likely to develop in children under the age of 1 year and older than 12 years. The risk group for a non-smooth course and adverse outcomes are children with concomitant diseases: genetic, neurological, metabolic disorders, congenital heart defects, obesity, diabetes mellitus, bronchial asthma and other chronic lung diseases, sickle cell anemia, oncopathology, immunodeficiency states. At present, various types of vaccines are used for specific prevention in the world: based on M-RNA technologies, vectorial, inactivated. These vaccines are effective and safe in reducing the burden of disease in eligible adolescents. Despite the emergence of new strains of circulating viruses, vaccines continue to be effective in preventing severe infections, hospitalization and death.